BioSpace News Archive

Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for govorestat (AT-007) for the treatment of Classic Galactosemia by three months.

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2023.

Predictive Oncology, a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, reported financial and operating results for the year ended December 31, 2023, and provided a corporate update.

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare’s novel SHP2.

Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results.

Nested Therapeutics today announced that preclinical data from its lead program, NST-628, will be featured in an oral presentation in the “New Drugs on the Horizon” series at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 5-10, 2024.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the clinical development plan intended to enable resubmission of a New Drug Application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease to the U.S. Food and Drug Administration (FDA).

Seres Therapeutics, Inc. announced that on March 25, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 700,000 shares of its common stock to Marella Thorell, the Company’s new Executive Vice President and Chief Financial Officer, consisting entirely of stock options.

Pluri Inc., a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, announced leadership from its business verticals will be presenting at, and participating in, the following conferences.

Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.